Get the Stockscreener App
8.26
1.85%
0.15
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Zynex Inc stock is traded at $8.26, with a volume of 63,061.
It is up +1.85% in the last 24 hours and down -3.17% over the past month.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
See More
Previous Close:
$8.11
Open:
$8.17
24h Volume:
63,061
Relative Volume:
0.63
Market Cap:
$263.04M
Revenue:
$193.67M
Net Income/Loss:
$4.82M
P/E Ratio:
17.96
EPS:
0.46
Net Cash Flow:
$15.53M
1W Performance:
+5.90%
1M Performance:
-3.17%
6M Performance:
-21.11%
1Y Performance:
-9.03%
1-Day Range:
$8.125
$8.30
1-Week Range:
$7.70
$8.30
52-Week Range:
$7.15
$13.77
Zynex Inc Stock (ZYXI) Company Profile
Name
Zynex Inc
Sector
Industry
Phone
(800)-495-6670
Address
9655 MAROON CIRCLE, ENGLEWOOD, CO
Compare ZYXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ZYXI | 9.30 | 0 | 0 | 0 | 0 | 0.00 |
| GOODO | 21.91 | 372.90M | 0 | 0 | 0 | 0.00 |
| PSNYW | 0.1388 | 292.92M | 2.07B | -1.42B | -1.37B | -0.1344 |
| MOBBW | 0.145 | 278.60M | 0 | 0 | 0 | 0.00 |
| SHMD | 2.48 | 106.79M | 0 | 0 | 0 | 0.00 |
| JUNE | 5.00 | 65.04M | 0 | 0 | 0 | 0.00 |
Zynex Inc Stock (ZYXI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-23 | Initiated | RBC Capital Mkts | Outperform |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Jul-16-21 | Upgrade | B. Riley Securities | Neutral → Buy |
| Mar-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Feb-26-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-28-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Sep-14-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-09-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-29-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jul-20-20 | Initiated | Piper Sandler | Overweight |
| Jul-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-10-20 | Reiterated | H.C. Wainwright | Neutral |
| Jun-16-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-19-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-01-20 | Initiated | Northland Capital | Outperform |
| Sep-23-19 | Initiated | H.C. Wainwright | Buy |
View All
Zynex Inc Stock (ZYXI) Latest News
Zynex Sets Third Quarter 2024 Earnings Call - GuruFocus.com
Zynex Medical COO discusses expanding role in non-opioid pain management - Proactive Investors UK
Zynex CEO Thomas Sandgaard sells shares worth $16,180 By Investing.com - Investing.com Canada
Zynex CEO Thomas Sandgaard sells shares worth $16,180 - Investing.com
PRESIDENT, CEO AND CHAIRMAN Sandgaard Thomas sold $16,180 worth of shares (2,000 units at $8.09), decreasing direct ownership by 0.01% to 14,603,662 units (SEC Form 4) - Quantisnow
Zynex, Inc Founder and CEO Thomas Sandgaard to participate in Benzinga's Pharma Companies vs. A Tough Macro Backdrop Free Webinar on August 3rd at 12:15 PM ET - Quantisnow
Insider Sale: Thomas Sandgaard Sells 10,000 Shares of Zynex Inc (ZYXI) - GuruFocus.com
Zynex CEO Thomas Sandgaard sells $89,280 in stock By Investing.com - Investing.com Canada
Zynex CEO Thomas Sandgaard sells $89,280 in stock - Investing.com
Building Momentum: Zynex Inc.'s (NASDAQ: ZYXI) Steady Rise in the Pain Management Market - openPR
Muscle Stimulation Devices Market Global Industry Growth - openPR
Insider Sale: President, CEO, and Chairman Thomas Sandgaard Sells Shares of Zynex Inc (ZYXI) - GuruFocus.com
Zynex CEO Thomas Sandgaard sells shares worth $51,080 - Investing.com India
Zynex CEO Thomas Sandgaard sells shares worth $51,080 By Investing.com - Investing.com UK
PRESIDENT, CEO AND CHAIRMAN Sandgaard Thomas sold $51,080 worth of shares (6,000 units at $8.51), decreasing direct ownership by 0.04% to 14,615,662 units (SEC Form 4) - Quantisnow
Trend Tracker for (ZYXI) - Stock Traders Daily
Insider Sale: CFO Daniel Moorhead Sells 10,000 Shares of Zynex I - GuruFocus.com
Zynex CFO Daniel Moorhead sells $85,900 in stock By Investing.com - Investing.com Australia
Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead Sells 10,000 Shares - MarketBeat
Zynex CFO Daniel Moorhead sells $85,900 in stock - Investing.com
Zynex, Inc. (NASDAQ:ZYXI) CEO Sells $17,260.00 in Stock - MarketBeat
Zynex CEO Thomas Sandgaard sells $52,740 in stock - Investing.com India
Insider Sale: Thomas Sandgaard Sells Shares of Zynex Inc (ZYXI) - GuruFocus.com
Zynex CEO Thomas Sandgaard sells $52,740 in stock By Investing.com - Investing.com Australia
Zynex's (NASDAQ:ZYXI) Soft Earnings Are Actually Better Than They Appear - Yahoo Finance
Zynex (ZYXI) Stock Forecast and Price Target 2024 - MarketBeat
Zynex Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly - Simply Wall St
Zynex, Inc. (NASDAQ:ZYXI) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Zynex reports steady Q3 growth, plans for future expansion - Investing.com India
Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates - MSN
How To Trade (ZYXI) - Stock Traders Daily
Earnings call: Zynex reports steady Q3 growth, plans for future expansion By Investing.com - Investing.com South Africa
Zynex (NASDAQ:ZYXI) Posts Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Zynex (NASDAQ:ZYXI) Price Target Raised to $17.00 - MarketBeat
Zynex shares target increased, buy rating held on strong Q3 results - Investing.com
Zynex Inc (ZYXI) Q3 2024 Earnings Call Highlights: Navigating Gr - GuruFocus.com
Zynex Inc (ZYXI) Q3 2024 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance
Proactive financial news: fast, accessible, and actionable articles and videos for the global investment audience. - Proactive Investors USA
Zynex (NASDAQ:ZYXI) Updates FY 2024 Earnings Guidance - MarketBeat
Zynex sees pain management orders increase in Q3 following FDA approval - Proactive Investors UK
Zynex Reports Third Quarter 2024 Financial Results - PR Newswire
Sales, strategy, and saving lives: A conversation with Zynex CEO Thomas Sandgaard - Proactive Investors USA
Preview: Zynex's Earnings - Benzinga
Pain Management Devices Market Report 2024 and Company Benchmarking for Abbott, Medtronic, Zynex Medical, Boston Scientific and OMRON Healthcare - Yahoo Finance
Womens Health Rehabilitation Products Market to Witness Huge - openPR
Zynex, Inc. (NASD: ZYXI) Wins 2023 National Top Workplaces Award in the Manufacturing Industry Category - GuruFocus.com
Zynex Sets Third Quarter 2024 Earnings Call – Company Announcement - Financial Times
AQR Capital Management LLC Sells 67,148 Shares of Zynex, Inc. (NASDAQ:ZYXI) - MarketBeat
Millennium Management LLC Acquires 118,615 Shares of Zynex, Inc. (NASDAQ:ZYXI) - Defense World
Zynex, Inc.: 2025 Looks Like A Brighter Year (NASDAQ:ZYXI) - Seeking Alpha
Zynex Inc Stock (ZYXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):